[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1624057T3 - Hyaluronidase-containing preparation as well as its pharmaceutical use - Google Patents

Hyaluronidase-containing preparation as well as its pharmaceutical use

Info

Publication number
DK1624057T3
DK1624057T3 DK05090293T DK05090293T DK1624057T3 DK 1624057 T3 DK1624057 T3 DK 1624057T3 DK 05090293 T DK05090293 T DK 05090293T DK 05090293 T DK05090293 T DK 05090293T DK 1624057 T3 DK1624057 T3 DK 1624057T3
Authority
DK
Denmark
Prior art keywords
fraction
hyaluronidase
well
purified
pharmaceutical use
Prior art date
Application number
DK05090293T
Other languages
Danish (da)
Inventor
Below Gudrun Von
Bernhard Schweigle
Bernd Goericke
Original Assignee
Riemser Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7833389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1624057(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Riemser Arzneimittel Ag filed Critical Riemser Arzneimittel Ag
Application granted granted Critical
Publication of DK1624057T3 publication Critical patent/DK1624057T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Production of a preparation containing hyaluronidase (I) involves (1) comminuting mammalian (especially steer) testes to a slurry, (2) eluting proteins and enzymes from with acid, (3) fractionally precipitating the eluate with ammonium sulphate (AS) to form a (I)-containing precipitate fraction, (4) dialysing this fraction to remove AS, (5) purifying the dialysate by adsorption-desorption on hydrated alumina and (6) using the purified (I) to produce galenic formulations. The novel features are that AS precipitation is effected in two steps, firstly at 10-29 wt.% then at 15-65 wt.%; and that the purified fraction from (5) is subjected to ulltrafiltration at an exclusion limit of 5-30 kD before formulating in step (6).
DK05090293T 1997-06-17 1998-06-15 Hyaluronidase-containing preparation as well as its pharmaceutical use DK1624057T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19726626A DE19726626C1 (en) 1997-06-17 1997-06-17 Preparation of composition comprising purified hyaluronidase

Publications (1)

Publication Number Publication Date
DK1624057T3 true DK1624057T3 (en) 2008-09-15

Family

ID=7833389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05090293T DK1624057T3 (en) 1997-06-17 1998-06-15 Hyaluronidase-containing preparation as well as its pharmaceutical use

Country Status (6)

Country Link
EP (2) EP0892045B1 (en)
AT (2) ATE323760T1 (en)
CZ (1) CZ289560B6 (en)
DE (3) DE19726626C1 (en)
DK (1) DK1624057T3 (en)
ES (2) ES2306004T3 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
DE19726626C1 (en) * 1997-06-17 1998-09-03 Pharma Dessau Gmbh Preparation of composition comprising purified hyaluronidase
CA2522544A1 (en) * 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
CN103725659A (en) * 2013-11-24 2014-04-16 青岛康原药业有限公司 Method for extracting hyaluronidase from bovine testes
DE102015107307B3 (en) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optical method for assaying hyaluronic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD24229A (en) *
US3708575A (en) * 1970-05-13 1973-01-02 Biorex Laboratories Ltd Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
RU2027759C1 (en) * 1992-02-03 1995-01-27 Пак Владимир Николаевич Method of hyaluronidase preparing
RU2054943C1 (en) * 1992-03-30 1996-02-27 Харьковское предприятие по производству иммунобиологических и лекарственных препаратов "Биолек" Method of hyaluronidase preparing
US5747027A (en) * 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
DE19726626C1 (en) * 1997-06-17 1998-09-03 Pharma Dessau Gmbh Preparation of composition comprising purified hyaluronidase

Also Published As

Publication number Publication date
DE59814240D1 (en) 2008-07-24
EP1624057A2 (en) 2006-02-08
EP1624057A3 (en) 2007-03-07
EP1624057B1 (en) 2008-06-11
ATE323760T1 (en) 2006-05-15
CZ289560B6 (en) 2002-02-13
ES2263190T3 (en) 2006-12-01
ATE398171T1 (en) 2008-07-15
EP0892045B1 (en) 2006-04-19
DE19726626C1 (en) 1998-09-03
CZ191098A3 (en) 1999-01-13
EP0892045A2 (en) 1999-01-20
DE59813491D1 (en) 2006-05-24
ES2306004T3 (en) 2008-11-01
EP0892045A3 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
NZ302984A (en) Multifunctional enzyme having N-terminal sequence IVGGXEVTPHAYPWQVGLFIDDMYF, where X is any amino acid
ATE124997T1 (en) ENZYMATIC REMOVAL OF AN AMINOTERMINAL PROTEIN SEQUENCE.
ATE234108T1 (en) THERAPEUTIC FOR SUPPRESSING SNORING NOISES
EP1396542A3 (en) P-Selectin Ligand Protein
BG106768A (en) Process for the purification of pharmacologically active proteins by cation-exchange chromatography
CA2259499A1 (en) Process for separating alpha-1-proteinase inhibitor from cohn fraction iv1 +iv4 paste
DK450785A (en) PROCEDURE FOR PREPARING A HIGH PURITY ANTIHAEMOPHILIC FACTOR CONCENTRATE
EP0111389A3 (en) Substantially pure porcine growth hormone, dna sequences therefor, and expression vehicles and transfected microorganisms for the production of porcine growth hormone
DK1624057T3 (en) Hyaluronidase-containing preparation as well as its pharmaceutical use
WO1995030001A3 (en) Novel p-selectin ligand protein
ATE43639T1 (en) PROCESSES FOR REMOVAL OF IMPURITIES FROM LEUKOCYTIN INTERFERON PREPARATIONS AND THE PURIFIED LEUKOCYTIN INTERFERON SO PRODUCED.
DE69837719D1 (en) PREPARATION OF LACTALBUMIN
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
EP0199568A3 (en) Method for purifying interferon and composition of matter produced thereby
AUPM772494A0 (en) Improvements in production of proteins in host cells
WO1998051780A3 (en) Method for increasing yields or recombinant proteins
ES8900224A1 (en) Methods for controlling the viscosity of protein hydrolysates.
FI962609A (en) Process for preparing xylitol
BG47043A3 (en) Method for isolating of d- aminoacid oxidase
RU96115481A (en) METHOD FOR TREATING DEFORMING OSTEOARTHROSIS OF LARGE JOINTS
NZ516235A (en) Method for purification of proteins
DE3270177D1 (en) Process for purifying elastase
EP0446850A3 (en) Process for purifying recombinant human beta-interferon
王榕树 et al. Physicochemical Behaviour and Removal of Lead in Water
AU8941091A (en) Method for purifying concentrated, aqueous and used solutions of chromic acid, and solutions thereby purified